ENTITY
Eli Lilly Becomes First Drugmaker to Reach $1 Trillion Valuation
Eli Lilly; trillion-dollar valuation; weight-loss drugs; Mounjaro; Zepbound; GLP-1 market; pharmaceutical industry; stock market; market capitalization
GSK and AnaptysBio Enter Legal Dispute Over Jemperli License Amid Allegations of Contract Breaches
GSK; AnaptysBio; Jemperli; dostarlimab; TESARO; litigation; license agreement; oncology; royalties; endometrial cancer
FDA Grants Regeneron Two Eylea HD Approvals in One Day
Regeneron; FDA approval; Eylea HD; macular edema; retinal vein occlusion; monthly dosing; aflibercept; ophthalmology; RVO
FDA Breakthrough Designations Lead to Priority Reviews, Report Finds
FDA; breakthrough therapy designation; priority review; drug approval; expedited pathway; biotechnology innovation; rare diseases; oncology; CDER; regulatory science
Aspen Neuroscience Secures $115 Million Series C to Advance Parkinson’s Cell Therapy; IPO Considered for 2026
Aspen Neuroscience; Series C financing; Parkinson’s disease; cell therapy; ANPD001; autologous iPSC; clinical trials; manufacturing scale-up; IPO plans; regenerative medicine
Researchers Advance Toward Matching Patients with the Most Effective GLP-1 Drug for Personalized Obesity Treatment
GLP-1; precision medicine; obesity; drug response prediction; genetic test; personalized care; side effects; machine learning; MyPhenome; Mayo Clinic; treatment adherence
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Inhibikase Therapeutics; public offering; common stock; pre-funded warrants; $100 million; Jefferies; BofA Securities; Cantor; clinical-stage pharmaceutical; pricing
Oncolytics Biotech Provides Update on Special Meeting of Shareholders
Oncolytics Biotech; special meeting; shareholders; rescheduling; government shutdown; jurisdiction change; Nevada; corporate update
ViVac Pharma Appoints Keren Leshem as CEO to Advance RNA-LNP Cancer Immunotherapy
ViVac Pharma; Keren Leshem; CEO appointment; RNA-LNP; cancer immunotherapy; leadership; biotechnology
Edgewise Therapeutics Appoints Christopher Martin to its Board of Directors
Edgewise Therapeutics; Christopher Martin; Board of Directors; biotech executive; commercial leadership; Becker muscular dystrophy; cardiovascular asset; Verona Pharma; Merck acquisition